|
Noninvasive Thymoma and Thymic Carcinoma
Current Clinical Trials
Standard treatment options:
- Surgical resection: Complete resection of a well-encapsulated, noninvasive
thymoma is usually curative and has a risk of local recurrence of less than
2%.[1] In patients with myasthenia gravis, operative mortality can be
minimized with close attention to respiratory support when planning surgical
treatment.
- Radiation therapy is not indicated following complete resection of a
well-encapsulated thymoma. Radiation therapy should be considered, however, in
rare cases when a noninvasive thymoma is incompletely resected, and when the
patient is a poor surgical risk.[1]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with thymoma and thymic carcinoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
McKenna WG, Bonomi P, Barnes MM, et al.: Malignancies of the thymus. In: Roth JA, Ruckdeschel JC, Weisenburger TH: Thoracic Oncology. Philadelphia, Pa: WB Saunders Co, 1989, pp 466-477.
Back to Top
< Previous Section | Next Section > |
